Abstract: A fused ring-containing compound, an application thereof, and a composition containing same, and specifically, a fused ring-containing compound represented by formula II, a pharmaceutically acceptable salt or solvate thereof, or a solvate of said pharmaceutically acceptable salt. The compound has good STAT5 inhibitory activity.

Abstract: A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Abstract: The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having a structure shown by the following formula (A1): or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof, that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.

Abstract: Disclosed is use of a compound in the preparation of a medicament for treating atherosclerosis. The compound is selected from a group consisting of a compound of formula I, Nib2 and a pharmaceutically acceptable salt thereof. Based on the mechanism of atherogenesis, the invention started with the inhibition of inflammatory reaction. The research results showed that the compounds disclosed herein can significantly inhibit the macrophage foaming, reduce the deposition of lipidic necrotic substances, and reduce the formation of plaques, thus to some extent delaying or inhibiting atherosclerosis.

Abstract: The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having the structure as shown in chemical formula A, or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.

Abstract: The present invention relates to compounds according to general formula (I); to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as anti-infectives.

Abstract: The present invention relates to compounds according to general formula (I); to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as anti-infectives.